Check your eligibility now & get in touch with a study center
CHECK ELIGIBILITY

Study of Eltrombopag vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia (ITP) in Children

The purpose of this study is to determine if Eltrombopag is as effective of a treatment for patients with newly diagnosed Immune Thrombocytopenia (ITP) when compared to standard treatment.

Detailed Description

Participants will not be paid for their participation.

Simple Text Block

You can use content blocks to arrange your articles, large texts, instructions. Combine these blocks with media blocks to add illustrations and video tutorials. You can use various content blocks to work with your text. Add quotations, lists, buttons. Select your text to change its formatting or add links. You can use various content blocks to work with your text. Add quotations, lists, buttons. Select your text to change its formatting or add links.

Call 1800-9860-568 now to find out if you are eligible.

Age
1 - 17
Gender
All
NCT ID
TX10529
Phase
-1
Status
Recruiting Now
Medical Condition
immune thrombocytopenia

How is Plaque Psoriasis treated?

Medical Condition
A short sentence to introduce what to expect in the about condition section
Learn more
The Study
A short sentence to introduce what to expect in the about condition section
Learn more
About Clinical Trials
A short sentence to introduce what to expect in the about condition section
Learn more

Your Journey

01
Receiving the medication
You would receive etanercept (Enbrel) twice a week for 12 weeks and then once a week for 12 weeks. Etanercept, as well as study related medical care, is provided at no cost.
02
Visiting the study site
Study participation involves approximately 8 visits to your local study center over 6 to 7 months.
03
Follow-up
There would also be a follow-up telephone call 30days after completing the study. No visits are required after participation is complete.

Call 1800-9860-568 now to find out if you are eligible.